Hello and welcome to my Nuzzel newsletter!
I'm Ronny, International Neuroendocrine Cancer Advocate. Independent Patient Voice. Award winning WEGO Health Patient Leader, Cure Today Contributor, Featured 1 million + Blogger, Veteran.
Ronny Allan - Living with Neuroendocrine Neoplasms
– Jul 29, 2019, 5:00 AM
I first heard about this drug at ENETS Barcelona 2017 and then again in 2018. It's now starting to be discussed in USA including at the 2019 ASCO conference. It was known then as Sulfatinib but for reasons unclear to me it was changed later to…
A new taskforce will meet next week to kick-start the recovery of cancer services across the NHS in England. Charities believe the pandemic has led to a significant reduction in people being referred for urgent cancer treatment. Cancer Research UK…
Memorial Sloan Kettering Cancer Center
Julie Grisham Sunday
– Sep 19, 9:00 PM
View on MSKCC.org › Targeted therapies aim to block the activity of genes that cause cancer, providing a direct attack on tumors while sparing healthy cells. Identifying genes that trigger tumor growth is only the first hurdle to developing…
by Nauman Arif Jadoon, MRCP, FHEA, FRSPH This Reading Room is a collaboration between MedPage Today and: Incidentally discovered adrenal tumors are becoming more common with increasing use of cross-sectional imaging. Adrenal incidentalomas require…
Ronny Allan - Living with Neuroendocrine Cancer
– Aug 30, 2018, 5:19 AM
Curium and RadioMedix Inc. announce an exclusive agreement to develop and commercialize Cu-Dotatate, an investigational positron emission tomography (PET) diagnostic agent for patients with Neuroendocrine Tumors (NETs). RadioMedix is currently…
CLARINET FORTE is a prospective single-arm, open-label, exploratory, international Phase II study to explore the efficacy and safety of an increased Somatuline Autogel (lanreotide) dosing interval (120 mg every 14 days) in patients with metastatic…